Oramed Pharma(ORMP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Oramed Pharma
ORMP.US
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc.
4.675 T
ORMP.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking87/190
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE36.56%A
    • Profit Margin3202.50%A
    • Gross Margin0.65%E
  • Growth ScoreB
    • Revenue YoY0.00%D
    • Net Profit YoY431.80%A
    • Total Assets YoY48.68%A
    • Net Assets YoY37.43%A
  • Cash ScoreD
    • Cash Flow Margin-14.46%D
    • OCF YoY0.00%D
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio13.48%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

    TradingView·
    US
    ORMP
    +0.93%
    US
    IHI
    +1.00%
    US
    XHE
    +0.66%
    TradingView·
    US
    ORMP
    +0.93%
    US
    IHI
    +1.00%
    US
    XHE
    +0.66%

    Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

    Simplywall·
    US
    ORMP
    +0.93%
    US
    LFMD
    +1.42%
    US
    CERS
    +11.11%
    Simplywall·
    US
    ORMP
    +0.93%
    US
    LFMD
    +1.42%
    US
    CERS
    +11.11%

    Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS

    TradingView·
    US
    ORMP
    +0.93%
    TradingView·
    US
    ORMP
    +0.93%

    Oramed Pharma | 10-K: FY2025 Revenue: USD 2 M

    Earnings Watch·
    US
    ORMP
    +0.93%
    Earnings Watch·
    US
    ORMP
    +0.93%

    Lifeward Successfully Closes on Strategic Partnership with Oramed | LFWD Stock News

    StockTitan·
    US
    IHI
    +1.00%
    US
    ORMP
    +0.93%
    US
    XHE
    +0.66%
    StockTitan·
    US
    IHI
    +1.00%
    US
    ORMP
    +0.93%
    US
    XHE
    +0.66%
    © 2026 Longbridge｜Disclaimer